Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF

Xie,Honghu; Lu,Qicheng; Wang,Haitao; Zhu,Xianbo; Guan,Zhong

doi:10.3892/ol.2018.9695

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF

Authors:
- Honghu Xie
- Qicheng Lu
- Haitao Wang
- Xianbo Zhu
- Zhong Guan
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China
Published online on: November 14, 2018 https://doi.org/10.3892/ol.2018.9695
Pages: 933-936
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical effects of FOLFOX4 and TPF chemotherapy regimen on postoperative gastric cancer patients were investigated. A total of 60 patients admitted to the First People's Hospital of Changzhou receiving gastric cancer operation were selected and they were divided into two groups at random. Thirty patients in the FOLFOX4 group were treated with oxaliplatin, fluorouracil and leucovorin, while 30 patients in the TPF group were treated with paclitaxel, fluorouracil and cisplatin. The therapeutic effects, adverse reactions, quality of life and survival time of patients in the two groups were observed. The total effective rate of the FOLFOX4 group was 73.3%, which was significantly higher than that of the TPF group (43.3%), and the difference was statistically significant (P<0.05). The proportions of neurotoxicity and thrombocytopenia in the FOLFOX4 group were 56.7 and 33.3%, while those in the TPF group were 26.7 and 60%, respectively, and the differences were statistically significant (P<0.05). The increasing proportion of postoperative scores of the FOLFOX4 group was 46.7%, which was significantly higher than that of the TPF group (20%), and the difference was statistically significant (P<0.05). The 2‑ and 3‑year survival rates of the FOLFOX4 group were 63.3 and 50%, which were significantly higher than those of the TPF group (36.7 and 23.3%), and the differences were statistically significant (P<0.05). Therefore, the effective rate of FOLFOX4 regimen is high in the treatment of gastric cancer with relatively fewer adverse reactions, which has a certain advantage.

View Figures

View References

1	Nam S, Chung JW and Yang JY: WNT5A correlates with clinicopathological characteristics in gastric cancer: A meta-analysis. Cell Physiol Biochem. 41:33–40. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 3:CD0040642010.
3	Zou K, Yang S, Zheng L, Yang C and Xiong B: Efficacy and safety of target combined chemotherapy in advanced gastric cancer: A meta-analysis and system review. BMC Cancer. 16:7372016. View Article : Google Scholar : PubMed/NCBI
4	Duo-Ji MM, Ci-Ren BS, Long ZW, Zhang XH and Luo DL: Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: A network meta-analysis. Oncotarget. 8:37896–37911. 2017. View Article : Google Scholar : PubMed/NCBI
5	De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 92:1644–1649. 2005. View Article : Google Scholar : PubMed/NCBI
6	Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, et al: Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer. 91:453–458. 2004. View Article : Google Scholar : PubMed/NCBI
7	Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, et al: Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: Results of a phase II trial. BMC Cancer. 6:1252006. View Article : Google Scholar : PubMed/NCBI
8	Wu F, Zhang HG, Ran FW, Zhang XR and Shi YK: FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer. Ai Zheng. 27:413–417. 2008.(In Chinese). PubMed/NCBI
9	Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J, Diallo A, et al: Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: A study of 48 patients. Oncotarget. 7:37297–37304. 2016. View Article : Google Scholar : PubMed/NCBI
10	Kawada J, Nishino M, Hosoda Y, Hoshino H, Okano M, Nagai K, Okuyama M, Kim Y and Tsujinaka T: Analysis of 5-fluorouracil and leucovorin combined with weekly paclitaxel in advanced gastric cancer. Gan To Kagaku Ryoho. 43:1951–1953. 2016.(In Japanese). PubMed/NCBI
11	Kaasa T and Wessel J: The Edmonton functional assessment tool: Further development and validation for use in palliative care. J Palliat Care. 17:5–11. 2001.PubMed/NCBI
12	Ji L, Gu D, Tan X, Sun H and Chen J: A meta-analysis of clinical trials over regimens with or without cetuximab for advanced gastric cancer patients. J BUON. 22:900–904. 2017.PubMed/NCBI
13	Li R, Yu J and Wang C: Silibinin promotes the apoptosis of gastric cancer BGC823 cells through caspase pathway. J BUON. 22:1148–1153. 2017.PubMed/NCBI
14	Hofheinz R, Clouth J, Borchardt-Wagner J, Wagner U, Weidling E, Jen MH and Brück P: Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: A choice-based conjoint analysis study from Germany. BMC Cancer. 16:9372016. View Article : Google Scholar : PubMed/NCBI
15	Lordick F and Terashima M: Gastric cancer adjuvant therapy. Best Pract Res Clin Gastroenterol. 30:581–591. 2016. View Article : Google Scholar : PubMed/NCBI
16	Song H, Zhu J and Lu D: Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev. 7:CD0114612016.PubMed/NCBI
17	Elimova E and Ajani JA: Surgical resection first for localized gastric adenocarcinoma: Are there adjuvant options? J Clin Oncol. 33:3085–3091. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kim JY, Ryoo HM, Bae SH, Kang BW, Chae YS, Yoon S, Baek JH, Kim MK, Lee KH, Lee SA, et al: Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Res. 35:3531–3536. 2015.PubMed/NCBI
19	Yoshino S, Furuya T, Shimizu R, Ozasa H, Nishimura T, Fukuda S, Kawaoka T, Hazama S and Oka M: Combination phase II study of weekly paclitaxel and 5′-DFUR for unresectable or recurrent gastric cancer. Anticancer Res. 33:2629–2633. 2013.PubMed/NCBI
20	Wang X, Wang Y, Qiu M, Li Q, Li ZP, He B, Xu F, Shen YL, Gou HF, Yang Y, et al: Postoperative chemoradiotherapy in gastric cancer: A phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). Med Oncol. 28 Suppl 1:S274–S279. 2011. View Article : Google Scholar : PubMed/NCBI